Table 3.
Use of anticoagulants
| Patients (n = 1,935) | Patient-days (n = 12,756) | |
|---|---|---|
| Prophylactic anticoagulants |
|
|
| Subcutaneous LMWH |
535 (27.6) |
2,687 (21.1) |
| Subcutaneous UFHa |
1,044 (54.0) |
5,504 (43.1) |
| Therapeutic anticoagulants |
|
|
| Any therapeutic anticoagulant |
390 (20.2) |
1,693 (13.3) |
| Intravenous UFH |
284 (14.7) |
1,210 (9.5) |
| LMWH |
35 (1.8) |
119 (0.9) |
| Coumadin |
94 (4.9) |
324 (2.5) |
| Danaparoid |
5 (0.3) |
7 (0.05) |
| Otherb |
52 (2.7) |
168 (1.3) |
| Any of the above | 1,619 (83.7) | 9,589 (75.2) |
Anticoagulation management for the 1,935 patients included in this audit, and ICU patient-days. Some patients received more than one type of anticoagulation during their ICU stay. LMWH, low molecular weight heparin; UFH, unfractionated heparin. aRefers to doses of UFH that were not ordered to target an activated partial thromboplastin time. bThrombolytic agents (streptokinase, recombinant tissue plasminogen activator), argatroban, fondaparinux, eptifibatide, dabigatran, rivaroxaban.